[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Wednesday, 23 November 2005, 10:19 GMT
Merck shares hit as boss departs
Cancer drug Erbitux
Cancer treatment Erbitux has proved a success for Merck
Shares in Merck, the German drugs and chemicals firm, have fallen in the wake of boss Bernhard Scheuble's departure from the firm.

Merck announced Dr Scheuble's immediate exit from the company on Tuesday after the German stock market closed, giving no reason for his departure.

Analysts said Dr Scheuble may have had a disagreement with the Merck family over the firm's future strategy.

Merck shares were down 2.11 euros, or 2.8%, at 71.55 euros by mid-afternoon.

Sudden exit

Dr Scheuble had worked for Merck for 23 years, serving five years as chief executive.

We assume that the root cause was a disagreement over Merck's future strategy
Nomura

Analysts said the company's recent performance had been strong, due in part to a recovery in its liquid crystals unit which produces components for flat screen TV and mobile phone displays.

"Given the suddenness of his departure, we would surmise that Dr Scheuble had a falling-out with the Merck family," investment firm Nomura said in a report.

"This is unlikely to have been over the current performance of the company, which is good, so we assume that the root cause was a disagreement over Merck's future strategy."

The Merck family hold a controlling 73% stake in the business, most widely known for its treatments for cancer, heart disease and diabetes.

Dr Scheuble has been succeeded by vice-chairman Michael Roemer.




SEE ALSO:
Profits increase as Bayer revamps
31 Aug 04 |  Business
Bayer to buy Roche consumer arm
19 Jul 04 |  Business
Bayer to spin-off chemicals unit
07 Nov 03 |  Business
Bayer sticks to profit target
06 Aug 03 |  Business


RELATED INTERNET LINKS:
The BBC is not responsible for the content of external internet sites


PRODUCTS AND SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific